LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.
← catalyst calendarSponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Diagnostic
Enrollment
525estimated
Sites
57
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-20 | actual | When the study began enrolling |
| Primary completion | 2026-07-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure
Intervention
- Device: Investigational LUX-Dx ICM Implant
Primary outcome
what the primary-completion date above is the date OFHeart Failure Event Related Data will be assessed in all subjects through collection of reportable events and subsequent adjudication by the CEC.
measured Through study completion of approximately 4.5 year
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed